New cancer clinical trial: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer
Published on: October 30, 2018 at 11:00PM
Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Intervention: Drug: BAY 2315497 Injection
Sponsor: Bayer
Not yet recruiting
https://ift.tt/2qimYWJ Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Intervention: Drug: BAY 2315497 Injection
Sponsor: Bayer
Not yet recruiting
https://ift.tt/2qimYWJ Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer
Comments
Post a Comment